Boron trifluoride etherate → Benzyl 8-benzyl-7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-2-oxo-2H-chromen-3-ylcarbamate

HRID 1511234Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1511234
B(F)(F)F.CCOCC.[CH2:10]([C:17]1[C:18]([OH:39])=[CH:19][CH:20]=[C:21]2[C:26]=1[O:25][C:24](=[O:27])[C:23]([NH:28][C:29](=[O:38])[O:30][CH2:31][C:32]1[CH:37]=[CH:36][CH:35]=[CH:34][CH:33]=1)=[CH:22]2)[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=1.ClC(Cl)(Cl)C(=N)O[C@H:44]1[C@@H:49]2[O:50][C:51](=[O:53])[O:52][C@@H:48]2[C@@H:47]([O:54][CH3:55])[C:46]([CH3:57])([CH3:56])[O:45]1.C(N(CC)CC)C>C(Cl)Cl>[CH2:10]([C:17]1[C:18]([O:39][C@H:44]2[C@@H:49]3[O:50][C:51](=[O:53])[O:52][C@@H:48]3[C@@H:47]([O:54][CH3:55])[C:46]([CH3:57])([CH3:56])[O:45]2)=[CH:19][CH:20]=[C:21]2[C:26]=1[O:25][C:24](=[O:27])[C:23]([NH:28][C:29](=[O:38])[O:30][CH2:31][C:32]1[CH:37]=[CH:36][CH:35]=[CH:34][CH:33]=1)=[CH:22]2)[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=1

Komponenten

6

Edukt 4

HCID 8000Boron trifluoride etherateHCID 8471TriethylamineHCID 25138790Benzyl 8-benzyl-7-hydroxy-2-oxo-2H-chromen-3-ylcarbamateHCID 67094064(3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1.3]dioxolo[4,5-c]pyran-4-yl 2,2,2-trichloroacetimidate

Produkt 1

HCID 25140542Benzyl 8-benzyl-7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-2-oxo-2H-chromen-3-ylcarbamateAusbeute 39 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6344DichloromethaneLösungsmittel

Versuchsvorschrift

Boron trifluoride etherate (7.80 μL, 0.062 mmol) was added to 23e (80.0 mg, 0.21 mmol) and (3aR,4S,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3 aH-[1.3]dioxolo[4,5-c]pyran-4-yl 2,2,2-trichloroacetimidate (299 mg, 0.83 mmol) in anhydrous CH2Cl2 (5.20 mL). After stirring at room temperature for 48 hours, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO2, 40:1 CH2Cl2:Acetone) to give 25e as a colorless foam (47.0 mg, 39%): 1H MMR (CDCl3, 500 MHz) 8.22 (s, 1H), 7.46 (s, 1H), 7.35-7.27 (m, 5H), 7.17-7.06 (m, 5H), 6.86 (d, J=10 Hz, 1H), 6.01 (d, J=10 Hz, 1H), 5.65 (d, J=1.6 Hz, 1H), 5.23 (s, 2H), 5.16 (s, 2H), 4.77-4.70 (m, 1H), 4.10 (s, 1H), 3.50 (s, 3H), 3.28 (s, 1H), 3.16 (d, J=7.4 Hz, LH), 1.25 (s, 3H), 1.18 (s, 3H); 13C NMR (CDCl3, 125 MHz) 155.1, 153.2 (2C), 153.1, 148.6 (2C), 139.6 (2C), 128.7, 128.6 (2C), 128.4 (2C), 128.3 (2C), 128.3 (2C), 126.5, 126.2, 123.1, 122.4, 121.7, 117.6, 114.9, 111.5, 94.7, 82.8, 67.6, 60.6 (2C), 29.7, 27.6, 21.9; IR (film) νmax 2926, 2854, 2359, 2341, 1811, 1709, 1607, 1522, 1456, 1381, 1366, 1259, 1209, 1171, 1078, 1049, 968, 766, 700 cm−1; HRMS (ESI+) m/z: [M+H]+ calcd for C33H31NO10, 602.2026. found, 602.2053.

Aufarbeitung

  1. concentrationthe solvent was concentrated
  2. customThe residue was purified via column chromatography (SiO2, 40:1 CH2Cl2:Acetone)

Quellen und Nachweise

ORD-Eintrag
ord-19318b0ef9f447bfbb5c6e67ee745b53
Quelldatensatz
uspto-grants-2012_07
Patentnummer
US08212011B2

Notizen zur Reaktion

Wird geladen…